Core Viewpoint - Beikang Medical-B (2170.HK) has seen a significant stock price increase, rising over 12% to HKD 4.36, marking its sixth consecutive day of gains and reaching a new high since March 17 [1] Company Summary - The company announced that its Gems culture medium (embryo handling fluid VitBase) has officially received approval from the National Medical Products Administration (NMPA) [1] - This registration marks an important milestone for the localization of reproductive fluids in China, indicating that Beikang Medical has developed full industry chain capabilities from international acquisition to domestic registration conversion [1] - VitBase is part of the GEMS culture medium series developed by Beikang's subsidiary BMX (formerly Genea Biomedx) [1] - The approval reflects the government's support for the innovative transformation of medical products acquired overseas, positioning Beikang Medical as one of the few companies globally with CE, FDA, and TGA certifications for assisted reproductive fluids, covering the entire process of assisted reproduction [1]

Core Viewpoint - Beikang Medical has received approval for its embryo handling solution VitBase, marking a significant step in the domestic production of its GEMS embryo culture media series [1] Group 1: Product Approval and Significance - The approval of VitBase is the first domestic registration certificate for Beikang Medical's GEMS embryo culture media series, indicating a new chapter in the domestic production of assisted reproductive consumables [1] - GEMS embryo culture media is developed by Singapore's BMX company, which has a 30-year research history and is recognized globally for its assisted reproductive products [1] Group 2: Product Credentials and Market Position - The initial formula of GEMS was previously licensed to Cook Medical and has been favored by Chinese embryologists for 30 years [1] - Currently, 11 products have received EU CE certification, 8 products have been approved by the US FDA, and 11 products meet Australian TGA standards, covering the entire assisted reproductive process [1] Group 3: Clinical Impact - The VitBase embryo handling solution, when used in conjunction with Beikang Medical's previously approved Geri non-interfering time-lapse incubator, significantly enhances blastocyst formation rates, clinical pregnancy rates, and live birth rates after the first transfer [1]